Prevalence of factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians

Neuroendocrinology Letters

Volumn 28, Issue 5, 2007, Pages 699-703

  Nusier, Mohamad K ^a   Radaideh, Abdelrahman M ^b   Ababneh, Nida'a A ^c   Qaqish, Bara'ah M ^c   Al Zoubi, Renad ^a   Khader, Yousef ^a   Mersa, Janet Y ^d   Irshaid, Nidal M ^d   El Khateeb, Mohammed ^c  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b Ministry of Health Jordan   (Jordan)

^c THE UNIVERSITY OF JORDAN   (Jordan)

^d National Blood Centre   (Jordan)

Author keywords

APC resistance; Factor II G20210A; Factor V Leiden; Thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; PROTHROMBIN; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ADULT; AGED; AMPLICON; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; PREVALENCE; PROTEIN ANALYSIS; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE;

EID: 38049059803     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: Pathogenesis, Clinical Syndromes and Management. Blood. 1996; 87: 3531-3544.
2. Laffan MA, Tuddenham EG. Inherited thrombophilias. QJM. 1997; 90: 375-378.
3. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001; 344: 1222-1231.
4. Schafer AI. Hypercoagulable state: molecular genetics to clinical practice. Lancet. 1994; 344: 1739-1742.
5. Bauer KA, Rosenclaal FR, Heit A Hypercoagulability: too many tests, too much conflicting data. Hematology. 2002; 1: 353-368.
6. Seligshon U, Zivelin A. Thrombophilia as a Multigenic Disorder. Thromb Haemost 1997; 78: 297-301.
7. Martinelli I. Risk Factors in venous thromboembolism. Thromb Haemost. 2001; 86: 395-403.
8. Dahlbäck B, Carlsson M, Svesson PJ. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein c: prediction of a co-factor to activated protein C. Proc Natl Acad Sci. 1993; 90: 1004-1008.
9. Bertina RM, Koeleman BP, Koster T, Rosenclaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood co-agulation factor Associated with Resistance to Activate Protein C. Nature. 1994; 369: 64-66.
10. Dahlbäck B. Inherited Thrombophilia: resistance to activated protein C as a pathogenic Factor of Venous thromboembolism. Blood. 1995; 85: 607-614.
11. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for thrombosis. Thromb Research. 1995; 77: 1-43.
12. Svensson PJ, Dahlback B. Resistance of activated protein C as a basis for Venous Thrombosis. N Engl J Med. 1994; 330:517-522.
13. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343:1361-1362.
14. Poort SR, Rosenclaal FR, Reitsma PH, Bertina RM. A Common Genetic Variation in the 3′-Untranslated Region of the Prothrombin Gene is associated with Elevated Plasma Prothrombin levels and an increase in Venous Thrombosis. Blood. 1996; 88: 3698-3703.
15. Gruenwald M, Germowitz A, Beneke H, Guethner C, Griesse M. Coagulation factor II activity determination is not useful as a screening tool for the G20210A Prothrombin Gene Allele. Thromb Haemost. 2000; 84: 141-142.
16. Rodeghiero F and Tosetto A. The epidemiology of inherited thrombophilia: the VITA project. Thromb Haemost. 1997; 78: 636-640.
17. Rees DC, Cox M, Clegg JB. World distribution of Factor V Leiden. Lancet. 1996; 346: 1133-1134.
18. Dzimiri N, Meyer B. World distribution of FactorV Leiden. Lancet. 1996; 347: 481-482.
19. Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, Attaasio M, Prisco D, Gensini GF, Abbat R. Prevalence of Factor V Leiden Mutation in Non-European Population. Thromb Haemost 1997; 77: 329-331.
20. Awidi A, Shannak M, Besesio A, Kailani MA, Kailani MA, Omar N, Anshasi B. High prevalence of Factor V Leiden in Healthy Jordanian Arabs. Thromb haemost. 1999; 81: 582-584.
21. Irani hakemi N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor v Arg506 mutation-Leiden among apparently healthy Lebanese. Am. J Hemato. 2000; 65: 45-9.
22. Taher A, Khalil I, Shameddine A, El-Ahdab F, Bazarbachi A. High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the Eastern Mediterranean Region the area of Origin of this mutation?. Thromb Haemost 2001; 86: 723-724.
23. Lucotte G, Champenois T. Duplex PCR-RFLP for simultaneous detection of factor V Leiden and prothrombin G20210A. Mol Cell Probes. 2003 Oct; 17(5): 267-269.
24. Huber S, McMaster KJ, Voelkercling KV. Analytical Evaluation of Primer Engineered Multiplex Polymerase Chain Reaction-Restriction Fragment Length Polymorphism for Detection of Factor VLeiden and Prothrombin G20210A. Journal of Molecular Diagnostics, 2000; 2; 153-157
25. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995 85: 1504,
26. Eid SS, Rihani G. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in 200 healthy Jordanians. Clin Lab Sci. 2004; 17: 200-202.
27. Awidi A, Shannak M, Besesio A, Kailani MA, Kailani MA, Omar N, Anshasi B. High prevalence of Factor V Leiden in Healthy Jordanian Arabs. Thromb haemost. 1999; 81: 582-584.
28. Horne MK, McCloskey DJ. Factor V Leiden as a common genetic risk factor for venous thromboembolism. J Nurs Scholarsh. 2006; 38(1):19-25. Review.
29. Kalkanli S, Ayyildiz O, Tiftik N, Batun S, Isikdogan A, Ince H, Tekes S, Muftuoglu E. Factor V Leiden mutation in venous thrombosis in southeast Turkey. Angiology. 2006 Mar-Apr; 57(2): 193-196.
30. Almawi WY, Keleshian SH, Borgi L, Fawaz NA, Abboud N, Mtiraoui N, Mahjoub T. Varied prevalence of factor V G1691A (Leiden) and prothrombin G2021 OA single nucleoticle polymorphisms among Arabs. J Thromb Thrombolysis. 2005 Dec; 20(3): 163-168.
31. Pepe G, Rickards 0, Vanegas OC, Brunelli T, Gori AM, Giusti B, Attanasio M, Prisco D, Gensini GF, Abbate R. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost. 1997 Feb; 77(2): 329-31.
32. Koster T, Rosenclaal FR, cle Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein. Leiden Thrombophilia study. Lancet. 1993; 342: 1503-1506.
33. Zöller B, DahlUck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994; 343: 1536-1538.
34. Henkens CM, Bom VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein c; influence of oral Contraceptives and sex. Thromb Haemost. 1995; 73: 402-404.